ClinicalTrials.gg

Program

HRS-4508

A development code. Also written as “HRS-4508 tablet”, “HRS-6209 in Combination HRS-4508 and letrozole” and “HRS-4508+ Capecitabine”.

In Jiangsu HengRui Medicine's pipeline, HER2. Its studies are mostly in Breast Neoplasms · Lung Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Aug 1, 20245 company-led studies, 5 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine55 open or runningphase 2since Aug 1, 2024Aug 1, 2024Sep 2027phase 2 · NCT07003321
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-4508, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 1, 2024First study: phase 2 study in Breast NeoplasmsFirst studyNCT06555068 · 528 planned · China
  2. Sep 12, 2024Phase 1 study in Advanced Solid TumorsNCT06598735 · 290 planned · China
  3. May 26, 2025Phase 2 study in Solid TumorNCT07003321 · 120 planned · China
  4. Aug 17, 2025Phase 2 study in Solid TumorNCT07140393 · 120 planned · China
  5. Nov 14, 2025Phase 2 study in Lung NeoplasmsNCT07232849 · 100 planned · China

Ahead

  1. Sep 2027Primary completion: phase 2 study in Solid TumorNCT07003321
  2. Oct 2027Primary completion: phase 2 study in Solid TumorNCT07140393
  3. Dec 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07232849
  4. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068

TargetBeta

“HER2”the company's pipeline, read by Claude · source

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07232849Lung Neoplasms · China2RecruitingDec 2027100
NCT07140393Solid Tumor · China2RecruitingOct 2027120
NCT07003321Solid Tumor · China2RecruitingSep 2027120
NCT06598735Advanced Solid Tumors · China1RecruitingDec 30, 2027290
NCT06555068Breast Neoplasms · China2RecruitingDec 2027528

How it is read

Names in the registry

  • “HRS-4508 tablet”, 2 entries
  • “HRS-6209 in Combination HRS-4508 and letrozole”, 1 entry
  • “HRS-4508”, 1 entry
  • “HRS-4508+ Capecitabine”, 1 entry
  • “HRS-4508+ Trastuzumab”, 1 entry

Codes read as this program: HRS4508.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.